Efzimfotase alfa
Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP).
For research use only. We do not sell to patients.
- CAS No.: 2746354-58-3
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Fusion-[Homo sapiens ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase) 18-502]2-IGHG4 Fc (Fragment constant)-deca-aspartate
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
-
CPCA_[PROTEIN_BIG]2-FC
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2746354-58-3
-
SMILES
[Efzimfotase alfa]
-
Synonyms
ALXN-1850
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Dahir KM, et al. Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. Curr Osteoporos Rep. 2025 Mar 18;23(1):14. [Content Brief]
[2]. Dahir KM, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39(10):1412-1423. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)